Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan
TOKYO and CAMBRIDGE, Mass., Ja […]
Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024
NEW YORK, NY, Jan 16, 2023 […]
AJG Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
ROCKVILLE, MD and SHENZHEN, CH […]
ATAL’s Award-Winning AMSFS III Granted Patent in Mainland China
HONG KONG, Sep 15, 2022 – […]
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
Continuously expanding the sco […]
Angelalign Announces 2021 Annual Results
HONG KONG, Mar 25, 2022 – […]
Memiontec Secures its Largest Contract to date following Award of a New S$56.6 Million Contract by PUB
Singapore, Mar 25, 2022 – […]
IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Approved by FDA
HONG KONG, Mar 14, 2022 – […]
IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA
HONG KONG, Feb 17, 2022 – […]
AstraZeneca’s antibody drug for Covid-19 treatment to arrive in S’pore by end of the year
SINGAPORE – Singapore ha […]
